Orforglipron (Oral GLP-1)
Obesity and Type 2 Diabetes
Sponsor Eli Lilly
6,000 Enrollment Target
350 Trial Sites
5 Countries
September 2026 Est. Completion
About This Trial
Once-daily oral GLP-1 receptor agonist for weight management and glycemic control.
Primary Endpoints
- Percent weight change
- HbA1c reduction
Latest Update
February 2026
Phase 2 showed 14.7% weight loss at 36 weeks. Phase 3 on track for H2 2026 readout.